UNITY Biotechnology (UBX)
(Delayed Data from NSDQ)
$1.59 USD
0.00 (0.00%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $1.59 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
UNITY Biotechnology, Inc. [UBX]
Reports for Purchase
Showing records 1 - 20 ( 99 total )
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Differentiation in DME - Phase 2B UBX1325 Data on 2024 Horizon; Reducing PT to $8 With Model Adjustments, Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Q3: Runway Extended Beyond 16wk Ph2b Readout in Q4:24; Upgrade to OP
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Novel Senolytic UBX1325 Stands to Offer Differentiation in DME; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -Healthcare Coverage Update
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 ENVISION wAMD Impact and Focusing Attention on UBX1325 in DME; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
ENVISION Part B Results Show Continued Evidence of Activity for UBX1325
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Q2: Focus Remains on Advancing UBX1325 into Head-to-Head Ph2b vs. Aflibercept
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
UBX1325 Progress and Looking to Phase 2 ENVISION Trial 3Q23; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 In Line; Awaiting ENVISION Part B Results and ASPIRE Trial Start
Provider: Roth Capital Partners, Inc.
Analyst: DUPUIS D
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Ph2b Goes H2H Against Aflibercept; With Limited Cash Runway D/g to NEUTRAL
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2b DME Trial Design Revealed; Interim Results Expected 1Q25
Provider: Roth Capital Partners, Inc.
Analyst: DUPUIS D
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Views on Clinical Progress in the Retina-Highlights From Clinical Trials at the Summit 2023 Annual Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Beyond the Realms of VEGF; Initiating Buy, $10 PT
Provider: Roth Capital Partners, Inc.
Analyst: Research Department